←
Amanda Johnson, MD244 posts
Amanda Johnson, MD avatar

Amanda Johnson, MD

@amjohnsonMD

Gastroenterologist at @MayoClinicGIHep with clinical and research interests in #IBD and #obesity. Tweets are my own.

◷ Joined August 2017▧ 61 Photos and videos
Parakkal Deepak MD, MS, FACG avatar
⟳ Amanda Johnson, MD retweeted
Parakkal Deepak MD, MS, FACG@P_DeepakIBDMD·May 26

Protocol for the ongoing consensus work on this topic in IBD with my co-PIs @amjohnsonMD @AndresYarur and a super team including @jalpa_devi @SamiSamaanMD @phillyIBDdoc Matt Vincent Shannon Coombs @MouhandMD and RAND/UCLA methodologist @EdBarnesMD Stay tuned for the actual 3 part survey output: Modulate Obesity and relateD metabolic complIcations For Yielding improvements in IBD outcomes (MODIFY-IBD): consensus on obesity and cardiometabolic comorbidities in inflammatory bowel disease using systematic reviews and the RAND/UCLA appropriateness m… @BMJ_Open bmjopen.bmj.com/content/16/5…

Parakkal Deepak MD, MS, FACG avatar
⟳ Amanda Johnson, MD retweeted
Parakkal Deepak MD, MS, FACG@P_DeepakIBDMD·May 16

📢 New pub from #REBOOTIBD consortium and #NorthAmericanpCD group, longer tweet coming from @jalpa_devi Real-World Effectiveness of Upadacitinib for Perianal Crohn’s Disease: A Multi-Center Retrospective Study - @AGA_CGH in N =125 patients - 45.5% achieved clinical response, - 39.4% clinical remission. - On pelvic MRI (n=78), 55.1% improved and 11.5% completely healed. - Clinical response higher in anti-TNF–naïve vs. exposed (66.7% vs. 33.3%; p=0.001) - Clinical response higher in those with shorter disease (54.7% vs. 33.3%; p=0.04) pCD patients cghjournal.org/article/S1542…

Post attachment
Edward Loftus avatar
⟳ Amanda Johnson, MD retweeted
Edward Loftus@EdwardLoftus2·May 5

Come swing by the poster hall to see our Olmsted County IBD posters by Dr Mouhand Mohamed Tu1554,Tu1635, and Tu1650! One on Crohn’s surgery rates, another on steroids and hospitalizations in CD, and one on IBD natural history in those diagnosed >60 years!

Post attachmentPost attachmentPost attachment
Healio Gastroenterology avatar
⟳ Amanda Johnson, MD retweeted
Healio Gastroenterology@HealioGastro·May 5

🗨️ “The 10-year risk for #colectomy in patients with #UlcerativeColitis still appears to be approximately 15%,” Dr. Isabel Lopera said. Lopera, study PI @EdwardLoftus2 and mentor @amjohnsonMD reported results from 50+ years of data at #DDW2026. vist.ly/533fa

Beatriz Gros avatar
⟳ Amanda Johnson, MD retweeted
Beatriz Gros@Bealoquebea·Apr 14

This morning, while preparing a talk, I thought about how to represent the complexity of diagnosis and disease evolution Like white light passing through a prism, each wavelength travels at a different speed and bends differently, revealing a spectrum. Similarly, one disease can unfold in multiple ways, each specialist controls one color, but the patient is the whole light I thought it was a nice representation

Post attachment
Tauseef Ali MD, FACG AGAF FACP avatar
⟳ Amanda Johnson, MD retweeted
Tauseef Ali MD, FACG AGAF FACP@ibdtweets·Apr 13

Understanding the journey to an IBD diagnosis is key to unlocking early intervention. This detailed infographic breaks down "Pre IBD," the crucial preclinical phase where biological changes begin long before symptoms appear. From genetic predisposition to molecular initiation and subclinical inflammation, the path to Crohn’s disease or ulcerative colitis often spans years. Recognizing these early stages opens the window for prediction, risk stratification, and potentially interception. Dive into the science behind the "At Risk" phase, microbiome shifts, and disease-specific signals. linkedin.com/posts/ibd-libra…

Post attachment
Mayo Clinic Gastroenterology & Hepatology avatar
⟳ Amanda Johnson, MD retweeted
Mayo Clinic Gastroenterology & Hepatology@MayoClinicGIHep·Feb 5

Join expert bariatric endoscopists @DanMaselliMD & @EricJVargasMD for a FREE webinar February 18th on innovative, minimally invasive weight-loss procedures. Learn how endoscopic sleeve gastroplasty (ESG) and gastric fundal mucosal ablation (GFMA) work, who they’re for, and what results patients can expect—plus a live Q&A. Submit questions anytime to: endobariatrics@mayo.edu and don’t forget to register here! —> bit.ly/4awWUhm

Post attachment
Edward Loftus avatar
⟳ Amanda Johnson, MD retweeted
Edward Loftus@EdwardLoftus2·Jan 25

AGA Clinical Practice Update on Inpatient Management of Adults With #IBD : Expert Review gastrojournal.org/article/S0… @AmerGastroAssn @AGA_Gastro Over the next couple of days I am going to summarize the recommendations of this AGA CPU by @ShirleyCoMekMD @JHashashMD @IBDMD and me 🧵

Sun-Ho Lee, MD, PhD avatar
⟳ Amanda Johnson, MD retweeted
Sun-Ho Lee, MD, PhD@SunHoLee15·20 Dec 2025

📢 New in Gastroenterology from PROMISE group: Prediction and Prevention of Inflammatory Bowel Disease: A Call to Action Summarizing the key points from the May 2025 PROMISE Workshop @LopesScopes @khalili_MD @JeanFredericCo1 @KenCroitoru #IngaPeter pubmed.ncbi.nlm.nih.gov/4141…

Tauseef Ali MD, FACG AGAF FACP avatar
⟳ Amanda Johnson, MD retweeted
Tauseef Ali MD, FACG AGAF FACP@ibdtweets·20 Dec 2025

As gastroenterologists, we need to move past the outdated idea that IBD is only a disease of undernutrition. 📊 The evidence is clear: Obesity increases the risk of Crohn’s disease It is associated with more active disease and poorer outcomes It may reduce response to therapy And it increases surgical risk Visceral fat—especially mesenteric fat—is biologically active and can fuel intestinal inflammation. This has real implications for how we counsel patients, dose therapies, and design multidisciplinary care models. 💡 Obesity in IBD is not a failure—it’s a modifiable risk factor and an opportunity to improve outcomes. Proud to share this educational work through IBD Library™. @saia_gi @CrohnsColitisFn @CrohnsColitisUK @aboutIBD @getgutsycanada @gastrogirl @AmCollegeGastro @AmerGastroAssn linkedin.com/posts/ibd-libra…

Parakkal Deepak MD, MS, FACG avatar
⟳ Amanda Johnson, MD retweeted
Parakkal Deepak MD, MS, FACG@P_DeepakIBDMD·12 Oct 2025

GLP1-Receptor agonists & Clinical Outcomes of IBD: A Syst. Review/Meta-analysis. academic.oup.com/ecco-jcc/ar… 👉11 studies with 16,242 IBD pt Rx with GLP1-RAs 👉wt loss ~various GLP1RAs included 👉GLP1- RAs assoc 🔽risk of surgery 👉Sens. analysis: 🔽risk hosp./surgery in BMI≥30